Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference

Rhea-AI Summary

Inozyme Pharma, Inc. (Nasdaq: INZY) will participate in the Bank of America Securities 2024 Health Care Conference with CEO Doug Treco. The company focuses on developing therapeutics for rare diseases related to mineralization and intimal proliferation.

BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 from 6:40-7:10pm ET / 3:40-4:10pm PT.

A live webcast of the fireside chat can be accessed from the Investor Relations section of Inozyme’s website under events, where a replay of the event will also be available for a limited time.

About Inozyme Pharma

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. Inozyme is developing INZ-701, an enzyme replacement therapy, to address pathologic mineralization and intimal proliferation, which can drive morbidity and mortality in these severe diseases. INZ-701 is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.

For more information, please visit https://www.inozyme.com/ or follow Inozyme on LinkedIn, X, and Facebook.

Contacts

Investors:
Inozyme Pharma
Stefan Riley, Senior Director of IR and Corporate Communications
(857) 330-8871
stefan.riley@inozyme.com

Media:
SmithSolve
Matt Pera
(973) 886-9150
matt.pera@smithsolve.com

FAQ

When will Inozyme Pharma participate in the Bank of America Securities 2024 Health Care Conference?

Inozyme Pharma will participate on Wednesday, May 15, 2024, from 6:40-7:10pm ET / 3:40-4:10pm PT.

Who will represent Inozyme Pharma at the conference?

Doug Treco, Ph.D., the CEO and Chairman of Inozyme, will participate in a fireside chat.

What is the focus of Inozyme Pharma's therapeutics development?

Inozyme Pharma focuses on developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation.

Where can a live webcast of the fireside chat be accessed?

The live webcast can be accessed from the Investor Relations section of Inozyme’s website under events.